logo

Polarityte, Inc. (PTE)



Trade PTE now with
  Date
  Headline
1/18/2022 8:02:32 AM PolarityTE : FDA Approves IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication
12/20/2021 8:05:16 AM PolarityTE Submits Complete Response To FDA's Clinical Hold Correspondence For SkinTE IND
11/10/2021 7:02:31 AM PolarityTE Q3 Loss/shr Narrows To $0.01 From $0.18 Last Year
10/7/2021 8:05:44 AM PolarityTE Says Strongly Believe In Potential For SkinTE In Chronic Cutaneous Ulcers
9/2/2021 8:06:13 AM PolarityTE Names Richard Hague CEO; Elects David Seaburg To Board
8/24/2021 8:10:10 AM PolarityTE Says Study Proposed In The IND Has Been Placed On Clinical Hold
8/12/2021 4:04:01 PM PolarityTE Q2 Loss/share $0.04 Vs. Loss $0.33 Year Ago
7/28/2021 8:06:11 AM PolarityTE Says SkinTE Met Primary And Secondary Endpoints In Final Analysis From Diabetic Foot Ulcer Trial